

MEETING INVITATION

DECODING OSTEOPOROSIS

KEY QUESTIONS IN OSTEOPOROSIS ANSWERED



Friday 26 March 2021 | 1:00–2:00 pm

Covering the latest clinical guidelines with practical updates to help you stay informed. This meeting addresses key questions in osteoporosis management.

AGENDA

- 1.00 pm: Lunch
- 1.05 pm: Decoding Osteoporosis presentation
- 2.00 pm: Meeting close

PRESENTER

Dr Weiwen Chen

Endocrinologist

Date: Friday 26 March 2021

Time: 1:00–2:00 pm


Details: Virtual meeting

Meeting login details will be provided prior to the workshop

To RSVP please contact your Amgen representative
Annie Gardiner M: 0448 650 485 E: agardi01@amgen.com

Registrations close 19 March 2021

This education event is for Australian Healthcare Professionals only.



Before prescribing please review the full Product Information available from
www.amgen.com.au/Prolia.PI

For information on Prolia® or to report an adverse event involving Prolia®, please contact Prolia® Medical Information on 1800 646 998.

PBS information: Authority required (STREAMLINED) as treatment for osteoporosis.
Criteria Apply. Refer to PBS Schedule for full information.

PROLIA MINIMUM PRODUCT INFORMATION. INDICATIONS: Treatment of osteoporosis in postmenopausal women (PMO) to reduce risk of vertebral, non-vertebral and hip fractures. Treatment to increase bone mass in men with osteoporosis at increased risk of fracture. Treatment to increase bone mass in women and men at increased risk of fracture due to long-term systemic glucocorticoid therapy. **CONTRAINDICATIONS:** Hypocalcaemia. Hypersensitivity to denosumab, CHO-derived proteins or any component. Pregnancy and in women trying to get pregnant. **PRECAUTIONS:** Correct hypocalcaemia prior to initiating therapy. Monitor calcium in patients predisposed to hypocalcaemia. Adequate intake of calcium and vitamin D is important. Severe renal impairment. Skin infections. Evaluate patients for risk factors for osteonecrosis of the jaw (ONJ); use with caution in these patients. Rare reports of atypical femoral fractures. Multiple vertebral fractures may occur following discontinuation. In glucocorticoid-induced osteoporosis, fractures occur at higher BMD than PMO. **ADVERSE EFFECTS:** Common: hypercholesterolaemia, eczema, fracture, back pain, arthralgia, nasopharyngitis, pain in extremity, osteoarthritis, bronchitis, hypertension, headache, dyspepsia, urinary tract infection, upper abdominal pain, bone pain and alopecia. **DOSAGE AND ADMINISTRATION:** Single subcutaneous injection of 60 mg, once every 6 months. Ensure adequate intake of calcium and vitamin D. No dose adjustment required in the elderly or in renal impairment. **PRESENTATION:** Pre-filled syringe with automatic needle guard. Refer to full Product Information before prescribing – available from Amgen Australia Ph: 1800 646 998 or at www.amgen.com.au/Prolia.PI

PRIVACY POLICY

Amgen Australia collects your personal information to enable us to manage and promote our educational events and educational events convened by other organisations, follow-up with you about your experience at these events and engage with you for the purpose of our promotional activities. For this purpose, we may disclose your personal information to Amgen Australia's related entities, as well as to trusted third parties and suppliers who assist us in providing our products and services, and market research agencies. These related entities and third parties may be located in other countries including the United States of America and in Europe and Asia. Amgen Australia remains accountable for all personal information it discloses and takes appropriate measures to ensure that the confidentiality of your information is safeguarded.

For more information on privacy at Amgen, including how you may access or correct your personal information or make a privacy complaint, please see our privacy policy available at www.amgen.com.au/privacy/privacy_terms.html or contact our Privacy Officer at: Mail: Attn: Privacy Officer, Amgen Australia Pty Ltd, Level 7, 123 Epping Road, North Ryde NSW 2113 Email: privacyoffice@amgen.com Tel: +61 2 9870 1333.